Identification of benzofuran-3-yl(phenyl)methanones as novel SIRT1 inhibitors: Binding mode, inhibitory mechanism and biological action

European Journal of Medicinal Chemistry

Volumn 60, Issue , 2013, Pages 441-450

  Wu, Jiahui ^a   Li, Yi ^a   Chen, Kaixian ^a   Jiang, Hualiang ^a   Xu, Ming Hua ^a   Liu, Dongxiang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Benzofuran 3 yl(phenyl)methanones; Binding mode; Deacetylation; Inhibitor; SIRT1

Indexed keywords

(2 HYDROXY 5 METHOXYPHENYL)(5 HYDROXYBENZOFURAN 3 YL)METHANONE; (2,5 DIHYDROXYPHENYL)(5 HYDROXY 1 BENZOFURAN 3 YL)METHANONE; (2,5 DIMETHOXYPHENYL)(5 HYDROXYBENZOFURAN 3 YL)METHANONE; (4 BROMOPHENYL)(5 HYDROXY 2 METHYLBENZOFURAN 3 YL)METHANONE; (4 BROMOPHENYL)(5 HYDROXYBENZOFURAN 3 YL)METHANONE; (4 BROMOPHENYL)(5 HYDROXYNAPHTHO[1,2 B]FURAN 3 YL)METHANONE; (4 CHLOROPHENYL)(5 HYDROXYNAPHTHO[1,2 B]FURAN 3 YL)METHANONE; (4,6 DIBROMO 5 HYDROXYBENZOFURAN 3 YL)(PHENYL)METHANONE; (5 HYDROXY 2 METHOXYPHENYL)(5 HYDROXYBENZOFURAN 3 YL)METHANONE; (5 HYDROXYBENZOFURAN 3 YL)(2 HYDROXYPHENYL)METHANONE; (5 HYDROXYBENZOFURAN 3 YL)(3 HYDROXYPHENYL)METHANONE; (5 HYDROXYNAPHTHO[1,2 B]FURAN 3 YL)(4 METHOXYPHENYL)METHANONE; HYDROLASE INHIBITOR; NICOTINAMIDE; PROTEIN P53; SIRTUIN 1; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; COVALENT BOND; DRUG BINDING; DRUG IDENTIFICATION; DRUG MECHANISM; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; STRUCTURE ACTIVITY RELATION;

BENZOFURANS; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROQUINONES; MCF-7 CELLS; MOLECULAR STRUCTURE; SIRTUIN 1; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84872129954     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.12.026     Document Type: Article

References (35)

1. H. Daitoku, M. Hatta, H. Matsuzaki, S. Aratani, T. Ohshima, M. Miyagishi, T. Nakajima, and A. Fukamizu Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity Proc. Natl. Acad. Sci. U.S.A. 101 2004 10042 10047
2. J.G. Wood, B. Rogina, S. Lavu, K. Howitz, S.L. Helfand, M. Tatar, and D. Sinclair Sirtuin activators mimic caloric restriction and delay ageing in metazoans Nature 430 2004 686 689
3. F. Picard, M. Kurtev, N. Chung, A. Topark-Ngarm, T. Senawong, R. Machado De Oliveira, M. Leid, M.W. McBurney, and L. Guarente Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma Nature 429 2004 771 776
4. K.T. Howitz, K.J. Bitterman, H.Y. Cohen, D.W. Lamming, S. Lavu, J.G. Wood, R.E. Zipkin, P. Chung, A. Kisielewski, L.-L. Zhang, B. Scherer, and D.A. Sinclair Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 425 2003 191 196
5. H.Y. Cohen, C. Miller, K.J. Bitterman, N.R. Wall, B. Hekking, B. Kessler, K.T. Howitz, M. Gorospe, R. de Cabo, and D.A. Sinclair Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase Science 305 2004 390 392
6. A. Brunet, L.B. Sweeney, J.F. Sturgill, K.F. Chua, P.L. Greer, Y. Lin, H. Tran, S.E. Ross, R. Mostoslavsky, H.Y. Cohen, L.S. Hu, H.L. Cheng, M.P. Jedrychowski, S.P. Gygi, D.A. Sinclair, F.W. Alt, and M.E. Greenberg Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase Science 303 2004 2011 2015
7. V.M. Nayagam, X. Wang, Y.C. Tan, A. Poulsen, K.C. Goh, T. Ng, H. Wang, H.Y. Song, B. Ni, M. Entzeroth, and W. Stunkel SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents J. Biomol. Screen. 11 2006 959 967
8. M.C. Motta, N. Divecha, M. Lemieux, C. Kamel, D. Chen, W. Gu, Y. Bultsma, M. McBurney, and L. Guarente Mammalian SIRT1 represses forkhead transcription factors Cell 116 2004 551 563
9. H. Vaziri, S.K. Dessain, E. Ng Eaton, S.I. Imai, R.A. Frye, T.K. Pandita, L. Guarente, and R.A. Weinberg hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase Cell 107 2001 149 159
10. J. Landry, A. Sutton, S.T. Tafrov, R.C. Heller, J. Stebbins, L. Pillus, and R. Sternglanz The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases Proc. Natl. Acad. Sci. U.S.A. 97 2000 5807 5811
11. A.D. Napper, J. Hixon, T. McDonagh, K. Keavey, J.F. Pons, J. Barker, W.T. Yau, P. Amouzegh, A. Flegg, E. Hamelin, R.J. Thomas, M. Kates, S. Jones, M.A. Navia, J.O. Saunders, P.S. DiStefano, and R. Curtis Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1 J. Med. Chem. 48 2005 8045 8054
12. A. Mai, S. Massa, S. Lavu, R. Pezzi, S. Simeoni, R. Ragno, F.R. Mariotti, F. Chiani, G. Camilloni, and D.A. Sinclair Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors J. Med. Chem. 48 2005 7789 7795
13. M. Freitag, J. Schemies, T. Larsen, K. El Gaghlab, F. Schulz, T. Rumpf, M. Jung, and A. Link Synthesis and biological activity of splitomicin analogs targeted at human NAD(+)-dependent histone deacetylases (sirtuins) Bioorg. Med. Chem. 19 2011 3669 3677
14. K.J. Bitterman Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of Yeast Sir2 and human SIRT1 J. Biol. Chem. 277 2002 45099 45107
15. B.D. Sanders, K. Zhao, J.T. Slama, and R. Marmorstein Structural basis for nicotinamide inhibition and base exchange in Sir2 enzymes Mol. Cell 25 2007 463 472
16. H. Ota, E. Tokunaga, K. Chang, M. Hikasa, K. Iijima, M. Eto, K. Kozaki, M. Akishita, Y. Ouchi, and M. Kaneki Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells Oncogene 25 2006 176 185
17. J.M. Solomon, R. Pasupuleti, L. Xu, T. McDonagh, R. Curtis, P.S. DiStefano, and L.J. Huber Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage Mol. Cell. Biol. 26 2006 28 38
18. B. Peck, C.Y. Chen, K.K. Ho, P. Di Fruscia, S.S. Myatt, R.C. Coombes, M.J. Fuchter, C.D. Hsiao, and E.W. Lam SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2 Mol. Cancer Ther. 9 2010 844 855
19. E. Lara, A. Mai, V. Calvanese, L. Altucci, P. Lopez-Nieva, M.L. Martinez-Chantar, M. Varela-Rey, D. Rotili, A. Nebbioso, S. Ropero, G. Montoya, J. Oyarzabal, S. Velasco, M. Serrano, M. Witt, A. Villar-Garea, A. Inhof, J.M. Mato, M. Esteller, and M.F. Fraga Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect Oncogene 28 2008 781 791
20. SIRT1 fluorimetric drug discovery kit B.R. Laboratories A fluor de lys fluorescent assay system 2009
21. J.L. Avalos, K.M. Bever, and C. Wolberger Mechanism of sirtuin inhibition by nicotinamide: altering the NAD+ Cosubstrate Specificity of a Sir2 enzyme Mol. Cell 17 2005 855 868
22. L. Jin, W. Wei, Y. Jiang, H. Peng, J. Cai, C. Mao, H. Dai, W. Choy, J.E. Bemis, M.R. Jirousek, J.C. Milne, C.H. Westphal, and R.B. Perni Crystal structures of human SIRT3 displaying substrate-induced conformational changes J. Biol. Chem. 284 2009 24394 24405
23. J.U. Bowie, R. Luthy, and D. Eisenberg A method to identify protein sequences that fold into a known three-dimensional structure Science 253 1991 164 170
24. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility J. Comput. Chem. 30 2009 2785 2791
25. H. Nakamura Roles of electrostatic interaction in proteins Q. Rev. Biophys. 29 1996 1 90
26. J.C. Milne, P.D. Lambert, S. Schenk, D.P. Carney, J.J. Smith, D.J. Gagne, L. Jin, O. Boss, R.B. Perni, C.B. Vu, J.E. Bemis, R. Xie, J.S. Disch, P.Y. Ng, J.J. Nunes, A.V. Lynch, H. Yang, H. Galonek, K. Israelian, W. Choy, A. Iffland, S. Lavu, O. Medvedik, D.A. Sinclair, J.M. Olefsky, M.R. Jirousek, P.J. Elliott, and C.H. Westphal Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes Nature 450 2007 712 716
27. M. Pacholec, J.E. Bleasdale, B. Chrunyk, D. Cunningham, D. Flynn, R.S. Garofalo, D. Griffith, M. Griffor, P. Loulakis, B. Pabst, X. Qiu, B. Stockman, V. Thanabal, A. Varghese, J. Ward, J. Withka, and K. Ahn SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1 J. Biol. Chem. 285 2010 8340 8351
28. Y. Feng, J. Wu, L. Chen, C. Luo, X. Shen, K. Chen, H. Jiang, and D. Liu A fluorometric assay of SIRT1 deacetylation activity through quantification of nicotinamide adenine dinucleotide Anal. Biochem. 395 2009 205 210
29. X.M. Cheng, and X.W. Liu Microwave-enhanced one-pot synthesis of diversified 3-acyl-5-hydroxybenzofurans J. Comb. Chem. 9 2007 906 908
30. W.F. Hawse, K.G. Hoff, D.G. Fatkins, A. Daines, O.V. Zubkova, V.L. Schramm, W. Zheng, and C. Wolberger Structural insights into intermediate steps in the Sir2 deacetylation reaction Structure 16 2008 1368 1377
31. N. Kabra, Z. Li, L. Chen, B. Li, X. Zhang, C. Wang, T. Yeatman, D. Coppola, and J. Chen SirT1 is an inhibitor of proliferation and tumor formation in colon cancer J. Biol. Chem. 284 2009 18210 18217
32. J. Luo, A.Y. Nikolaev, S. Imai, D. Chen, F. Su, A. Shiloh, L. Guarente, and W. Gu Negative control of p53 by Sir2alpha promotes cell survival under stress Cell 107 2001 137 148
33. S. Lain, J.J. Hollick, J. Campbell, O.D. Staples, M. Higgins, M. Aoubala, A. McCarthy, V. Appleyard, K.E. Murray, L. Baker, A. Thompson, J. Mathers, S.J. Holland, M.J. Stark, G. Pass, J. Woods, D.P. Lane, and N.J. Westwood Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 13 2008 454 463
34. J. Min, J. Landry, R. Sternglanz, and R.M. Xu Crystal structure of a SIR2 homolog-NAD complex Cell 105 2001 269 279
35. R. Chenna, H. Sugawara, T. Koike, R. Lopez, T.J. Gibson, D.G. Higgins, and J.D. Thompson Multiple sequence alignment with the Clustal series of programs Nucleic Acids Res. 31 2003 3497 3500